Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) presented preclinical data showing that the combination of its CNS-selective GABAA modulator ganaxolone and diazepam ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE